| Bioactivity | CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation[1][2]. |
| Invitro | CDDD11-8 (0-3 μM，24 小时) 可抑制 MV4-11 和 MOLM-13 细胞中 c-MYC、MCL-1 和 XIAP 的表达[1]。CDDD11-8 剂量依赖性地抑制增殖（IC50 范围：281-734 nM），诱导细胞周期停滞，并增加细胞系的凋亡[2]。 0 --> CDDD11-8 相关抗体: |
| In Vivo | CDDD11-8 (0-125 mg/kg，口服，每日)可诱导肿瘤消退[1]。 Animal Model: |
| Name | CDDD11-8 |
| CAS | 2241659-94-7 |
| Formula | C24H26N6 |
| Molar Mass | 398.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Anshabo AT, et al. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers (Basel). 2022 Feb 22;14(5):1113. [2]. Mustafa EH, et al. Selective inhibition of CDK9 in triple negative breast cancer. Oncogene. 2023 Nov 24. |